Does Medica Cover Mounjaro?
The verdict
Conditional on most plans
Medica (Upper Midwest) covers Mounjaro for type 2 diabetes with prior authorization — this is a composite pattern inferred from the near-universal diabetes-only baseline; Medica's formulary is not as publicly detailed as national carriers, so verify specific criteria on the plan formulary. Mounjaro is not covered for weight loss under any line. Medicaid coverage is state-dependent across Medica's footprint. The weight-loss tirzepatide product is Zepbound, with separate coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Medica using your member ID.
Key facts
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes only — not weight loss. The weight-loss tirzepatide product is Zepbound, a separate FDA approval.
FDA drug labeling, Mounjaro (tirzepatide) prescribing information
Medica is an Upper Midwest insurer operating in Minnesota and surrounding states; its formulary details are not as publicly accessible as national PBM-owned carriers — verify coverage directly with the plan.
Medica Health Plans — member resources
The 2026 Medicare Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach the cap within 2–3 months and pay $0 for the rest of the year.
CMS.gov, Medicare Part D Redesign 2025–2026
Medicare vs. commercial coverage
Whether Medica covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D covers Mounjaro for type 2 diabetes only — not weight loss — at a specialty or non-preferred tier with prior authorization. The 2026 out-of-pocket cap is $2,100; most continuous users reach it within 2–3 months and pay $0 for the rest of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1, 2026 – Dec 31, 2027), which covers weight-loss-approved products only. Lilly savings card is not usable by Medicare beneficiaries. Verify your specific Medica Medicare plan formulary each year.
Commercial / Employer
Group & marketplace plans
Commercial and employer-sponsored Medica plans are expected to cover Mounjaro for type 2 diabetes with prior authorization based on the near-universal diabetes-only pattern; off-label weight-loss use (diagnosis code E66.x) is denied. Medica's drug-level formulary is not as publicly detailed as national PBM-owned carriers — verify on the Medica formulary or member services before assuming coverage. ACA/Individual plans cover Mounjaro for T2D with PA; weight-loss GLP-1s are commonly excluded. Medicaid coverage across Medica's Upper Midwest footprint is state-dependent — verify on the applicable state PDL. Commercially insured patients with coverage may pay as little as $25/month via the Lilly savings card (excludes government programs; expires 12/31/2026). Without coverage on a commercial plan, the card reduces cost to $499/month (max $647/month, up to 13 fills).
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills; expires 12/31/2026). Excludes all government programs.
List price with no coverage — before any manufacturer savings card.
With coverage
Varies by plan tier — not publicly published at the drug level for Medica. Verify on the Medica formulary or member services. Commercially insured patients with coverage may pay as little as $25/month via the Lilly savings card.
Typical monthly copay once prior authorization is approved.
Bridge program
Lilly Mounjaro Savings Card: commercially insured patients with coverage as little as $25/mo; without coverage $499/mo (up to 13 fills, expires 12/31/2026). Not available to Medicare, Medicaid, Medicare Advantage, or government program beneficiaries.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Medica's plan-level tier and cost-share are not publicly published — confirm directly with Medica member services or the plan formulary. Medicare Part D: 25% coinsurance after deductible until the $2,100 OOP cap; MFN $245/month mid-2026. Medicaid nominal (state-dependent).
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Search the Medica member portal or call member services
Log in to the Medica member portal or call the number on the back of your Medica card. Search for Mounjaro (tirzepatide) to confirm your tier, prior authorization requirement, and estimated cost-share. Because Medica's drug-level formulary details are not as publicly accessible as national carriers, direct contact with the plan is the most reliable method.
- 2
Have your prescriber prepare the prior authorization
Your prescriber will need to document your confirmed T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or higher within about 90 days, and a trial or failure of metformin. Verify with Medica's current PA criteria — as an Upper Midwest regional insurer, Medica's specific requirements may differ from the national PBM defaults.
- 3
For Medicaid, verify on your state PDL
Medica operates Medicaid managed care across several Upper Midwest states. Coverage details are state-dependent — check your state's Medicaid Preferred Drug List (PDL) or contact Medica Medicaid member services to confirm Mounjaro coverage for type 2 diabetes in your state.
Options if Medica won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Widely covered with PA across commercial and Medicaid plans; often placed ahead of Mounjaro in step-therapy sequences. Verify on Medica formulary.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative; often preferred tier with a lower list price than Mounjaro. Verify on Medica formulary.
Jardiance (empagliflozin) or Farxiga (dapagliflozin)
SGLT2 inhibitors approved for T2D with cardiovascular and renal benefits. May be part of step-therapy requirements before GLP-1 approval.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. Has separate coverage from Mounjaro. Weight-loss GLP-1 coverage across Medica's Medicaid footprint varies by state — verify on the applicable state PDL.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
No. Medica does not cover Mounjaro for weight loss. Mounjaro is FDA-approved for type 2 diabetes only, and off-label weight-loss prescriptions coded with obesity diagnoses are denied. The weight-loss tirzepatide product is Zepbound, with separate coverage. Weight-loss GLP-1 coverage across Medica's Medicaid footprint varies by state. Verify any weight-loss GLP-1 coverage on the Medica formulary or applicable state PDL.
Coverage is inferred from the near-universal diabetes-only pattern across insurers — Medica's formulary is not as publicly detailed as national PBM-owned carriers. The diabetes-only coverage with PA is the standard baseline across nearly all commercial and Medicare Part D plans. Verify your specific Medica plan coverage directly with the plan formulary or member services before relying on this general pattern.
Based on the composite baseline, Medica's PA for Mounjaro is expected to require a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within approximately 90 days, and a trial or failure of metformin (plus often one additional agent). Age 18 or older is required. Quantity limit is typically 4 pens per 28 days. Verify specific Medica criteria on the plan formulary or member services.
Yes, if you have commercial Medica coverage and Mounjaro is covered on your plan, you may pay as little as $25/month via the Lilly savings card. Without commercial coverage, the card reduces cost to $499/month (max $647/month, up to 13 fills, expires 12/31/2026). The card is not available to Medicare Part D, Medicare Advantage, Medicaid, or any government program beneficiaries.
No. The 2026 Medicare GLP-1 Bridge ($50/month copay, July 1, 2026 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is a diabetes drug. Medicare covers Mounjaro for type 2 diabetes under standard Part D with prior authorization, specialty-tier cost-share, and the $2,100 annual OOP cap.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Mounjaro? 2026 Guide | Curex
BCBS covers Mounjaro for type 2 diabetes with prior authorization — not for weight loss. The weight-loss tirzepatide is Zepbound, with separate coverage.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Mounjaro? HCSC 2026 | Curex
BCBS of Illinois (HCSC) covers Mounjaro for type 2 diabetes with PA — not weight loss. IL Medicaid covers T2D but excludes weight-loss GLP-1s.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
You just saw how tangled Mounjaro coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Mounjaro. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Medica before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.